Capricor/$CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ticker
$CAPR
Sector
Health
Primary listing
Employees
160
Headquarters
Website
Capricor Metrics
BasicAdvanced
$369M
-
-$1.42
0.86
-
Price and volume
Market cap
$369M
Beta
0.86
52-week high
$21.01
52-week low
$3.71
Average daily volume
2.5M
Financial strength
Current ratio
6.548
Quick ratio
6.484
Long term debt to equity
0.319
Total debt to equity
0.979
Profitability
EBITDA (TTM)
-55.783
Gross margin (TTM)
-232.78%
Net profit margin (TTM)
-317.13%
Operating margin (TTM)
-329.90%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-35.24%
Return on equity (TTM)
-75.39%
Valuation
Price to revenue (TTM)
18.028
Price to book
2.53
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
-6.635
Free cash flow yield (TTM)
-15.07%
Free cash flow per share (TTM)
-1.216
Growth
Revenue change (TTM)
-35.92%
Earnings per share change (TTM)
65.27%
3-year revenue growth (CAGR)
339.82%
10-year revenue growth (CAGR)
12.12%
3-year earnings per share growth (CAGR)
13.88%
10-year earnings per share growth (CAGR)
-14.49%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Capricor News
AllArticlesVideos
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
Business Wire·2 days ago
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Business Wire·2 weeks ago
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $369M as of August 09, 2025.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of August 09, 2025.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.